Oculis Holding Non Current Assets Total Over Time
| OCSAW Stock | 4.73 0.06 1.25% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Oculis Holding Performance and Oculis Holding Correlation. Oculis |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oculis Holding. If investors know Oculis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oculis Holding listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Oculis Holding AG is measured differently than its book value, which is the value of Oculis that is recorded on the company's balance sheet. Investors also form their own opinion of Oculis Holding's value that differs from its market value or its book value, called intrinsic value, which is Oculis Holding's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oculis Holding's market value can be influenced by many factors that don't directly affect Oculis Holding's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oculis Holding's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oculis Holding is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oculis Holding's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Non Current Assets Total Analysis
Compare Oculis Holding AG and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Non Current Assets Total Over Time
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EQ | 2.1 K | 2.1 K | 2.1 K | 2.1 K | 2.1 K | 2.1 K | 2.1 K | 2.1 K | 63.5 K | 108 K | 254 K | 1.6 M | 1.2 M | 1.2 M | 698.4 K |
| DMAC | 188.7 K | 3.6 M | 1.4 M | 288.9 K | 15.6 K | 14.3 K | 19.4 K | 308 K | 367 K | 217 K | 174 K | 112 K | 560 K | 485 K | 638.8 K |
| VALN | 7.5 M | 39.6 M | 38.4 M | 191 M | 166.6 M | 158.8 M | 115.7 M | 105.9 M | 103.9 M | 135.6 M | 140.7 M | 231.5 M | 196.7 M | 197.2 M | 110.7 M |
| VANI | 953.6 K | 953.6 K | 953.6 K | 885.6 K | 1.1 M | 1.5 M | 1.5 M | 1.3 M | 1.1 M | 3.5 M | 2.8 M | 3 M | 3.6 M | 22.7 M | 23.9 M |
| DNLI | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 89.1 M | 77.1 M | 181.1 M | 123.2 M | 108.6 M | 506.9 M | 87.9 M | 89.8 M | 154.9 M |
| DNTH | 508 K | 508 K | 508 K | 508 K | 508 K | 508 K | 508 K | 2 M | 12 M | 11.7 M | 10.1 M | 63 K | 1.1 M | 2 M | 1.9 M |
| DOMH | 1.5 M | 127.1 K | 49.6 K | 66.6 M | 56.7 M | 9.8 M | 5 M | 4.6 M | 10.3 M | 10.2 M | 2.8 M | 11.8 M | 25.6 M | 29.4 M | 30.9 M |
| VCEL | 1.2 M | 1.6 M | 1.2 M | 739 K | 6.1 M | 7 M | 3.9 M | 4.1 M | 5.9 M | 41.6 M | 82 M | 85.2 M | 86.1 M | 148 M | 155.4 M |
| VCNX | 730 K | 730 K | 730 K | 730 K | 730 K | 730 K | 730 K | 601 K | 604 K | 594 K | 416 K | 438 K | 499 K | 282 K | 416.4 K |
| VCYT | 1.9 M | 1.9 M | 2.7 M | 3.2 M | 21.5 M | 27.4 M | 27.4 M | 24.7 M | 23.7 M | 87.5 M | 81.5 M | 944.7 M | 907.8 M | 829.3 M | 870.7 M |
Oculis Holding AG and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Non Current Assets Total description
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.My Equities
My Current Equities and Potential Positions
| Oculis Holding AG | OCSAW |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Exchange | NASDAQ Exchange |
null 4.73
Additional Tools for Oculis Stock Analysis
When running Oculis Holding's price analysis, check to measure Oculis Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oculis Holding is operating at the current time. Most of Oculis Holding's value examination focuses on studying past and present price action to predict the probability of Oculis Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oculis Holding's price. Additionally, you may evaluate how the addition of Oculis Holding to your portfolios can decrease your overall portfolio volatility.